The effect of celecoxib in the treatment of gastric metaplasia
Phase 4
- Conditions
- gastric intestinal metaplasia.
- Registration Number
- IRCT20230408057842N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Patients over 18 years old
All patients were diagnosed with gastric metaplasia
Exclusion Criteria
Patients with malignancy
Patients who had been treated with regular nonsteroidal anti-inflammatory drugs (NSAIDs), proton-pump inhibitors, bismuth salts, or antibiotics within two weeks before endoscopy
heart failure
renal dysfunction
pregnancy
liver cirrhosis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Gastric metaplasia alleviation. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: endoscopy and biopsy result.;Helicobacter pylori eradication. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: endoscopy and biopsy result.
- Secondary Outcome Measures
Name Time Method Improvement of dyspepsia symptoms. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Dyspepsia symptom assessment questionnaire.